IF we were talking about a company such as ours that had an approval or two under its belt, had contracts in place both on the production and sales side, was listed versus otc., I am all in on your analysis.
But, we are not there. yet. As of now, we are where the mm's and as of late, where the 13d's allow us to be, because they still profit from f'ing with us. Both of our protagonists know that we will get that elusive first approval and once we do, both will climb aboard for the ride.
Pricing in or not of any one future event now is not relevant. Just look at the history of the pr's, conference calls, hit-piece articles, and even the pro LL ones.
A whole lot of the smaller retail investors are just as fickle owning this bio tech startup as they are owning one share of Apple, Tesla, etc.